Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients

Acta Haematologica

Volumn 127, Issue 4, 2012, Pages 221-227

  Zhong, Jian Sheng ^a   Meng, Fan Yi ^b   Xu, Dan ^b   Zhou, Hong Sheng ^b   Dai, Min ^b  

^a GUANGZHOU RED CROSS HOSPITAL   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Chronic myeloid leukemia; Concentration; Efficacy; Imatinib

Indexed keywords

ALPHA1 GLYCOPROTEIN; IMATINIB; MESSENGER RNA; ORGANIC CATION TRANSPORTER 1;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER PATIENT; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; BONE MARROW CELLS; CHILD; CHINA; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; ORGANIC CATION TRANSPORTER 1; P-GLYCOPROTEIN; PIPERAZINES; PYRIMIDINES; RNA, MESSENGER; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859128208     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000336244     Document Type: Article

References (28)

1. Savage DG, Antman KH: Imatinib mesylate -a new oral targeted therapy. N Engl J Med 2002; 346: 683-693 (Pubitemid 34815874)
2. Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, Hatfield AK, Mone M, Filian J, Reynolds J, Gathmann I, Larson RA, Druker BJ: International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH Annual Meeting Abstracts. Blood 2009; 114: 1126
3. Campbell LJ, Patsouris C, Rayeroux KC, Somana K, Januszewicz EH, Szer J: BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer Genet Cytogenet 2002; 139: 30-33 (Pubitemid 36120403)
4. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880 (Pubitemid 32743979)
5. Walz C, Sattler M: Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 2006; 57: 145-164 (Pubitemid 43140744)
6. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA, Lassalle R, Marit G, Reiffers J, Begaud B, Moore N, Molimard M, Mahon FX: Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109: 3496-3499 (Pubitemid 46572540)
7. National Comprehensive Cancer Network: Clinical practice guidelines in oncology: chronic myelogenous leukemia. Version 2. www.nccn.org (accessed 2008)
8. Baccarani M, Pane F, Saglio G: Monitoring treatment of chronic myeloid leukemia. Haematologica 2008; 93: 161-169
9. Hehlmann R, Hochhaus A, Baccarani M: Chronic myeloid leukemia. Lancet 2007; 370: 342-350
10. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37 (Pubitemid 43990609)
11. Bakhtiar R, Lohne J, Ramos L, Khemani L, Hayes M, Tse F: High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 768: 325-340 (Pubitemid 34158868)
12. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R: Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935-942 (Pubitemid 34520420)
13. Thomas J, Wang L, Clark RE, Pirmohamed M: Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739-3745 (Pubitemid 39564452)
14. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y: Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111: 4022-4028
15. Mahon FX, Molimard M: Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia. Leuk Res 2009; 33: 1147-1150
16. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, Quinn SR, Manley PW, Hughes TP: OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006; 108: 697-704 (Pubitemid 44061372)
17. Umehara KI, Iwatsubo T, Noguchi K, Kamimura H: Functional involvement of organic cation transporter1 (OCT1/Oct1) in the hepatic uptake of organic cations in humans and rats. Xenobiotica 2007; 37: 818-831 (Pubitemid 47267805)
18. White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, Zannettino A, Lynch K, Manley PW, Hughes T: Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110: 4064-4072 (Pubitemid 350248463)
19. White DL, Saunders VA, Dang P, Frede A, Eadie L, Soverini S, Quarantelli F, Lin P, Thornquist M, Kim D, Pane F, Martinelli G, Radich J, Kalebic T, Saglio G, Hughes T: CML patients with low OCT-1 activity achieve better molecular responses on high dose imatinib than on standard dose. Those with high OCT-1 activity have excellent responses on either dose: a TOPS correlative study. ASH Annual Meeting Abstracts. Blood 2008; 112: 3187
20. Fojo T, Coley HM: The role of efflux pumps in drug-resistant metastatic breast cancer: new insights and treatment strategies. Clin Breast Cancer 2007; 7: 749-756 (Pubitemid 350086119)
21. Mao Q, Unad, Kruh GD, Belinsky MG: The MRP family of drug efflux pumps. Oncogene 2003; 22: 7537-7552 (Pubitemid 37487175)
22. kat JD: Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 2005; 7:E118-E133
23. Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF: Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003; 304: 1085-1092 (Pubitemid 36254421)
24. Dohse M, Robey RW, Brendel C, Bates S, Neubauer A, Scharenberg C: Efflux of the tyrosine kinase inhibitors imatinib and nilotinib (AMN107) is mediated by ABCB1 (MDR1)-type P-glycoprotein. ASH Annual Meeting Abstracts. Blood 2006; 108: 1367
25. Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlagel U, von Bonin M, Pursche S, Bergemann T, Ehninger G, Schleyer E: P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18: 401-408 (Pubitemid 38425851)
26. Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J, Goldman JM, Melo JV: MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368-2373 (Pubitemid 36304670)
27. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037 (Pubitemid 32267972)
28. Peng B, Lloyd P, Schran H: Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44: 879-894. (Pubitemid 41252840)